AMGEN at the American Heart Association's (AHA) Scientific Sessions 2022

Addressing Gaps in Cardiovascular Health

Cardiovascular disease is one of the most significant public health issues in the world. Our commitment to cardiovascular disease remains steadfast, and supporting cross-sector collaborative programs and patient-advocacy initiatives is part of this commitment. A key focus of this work is moving from a reactive healthcare model toward a proactive and innovative public health approach aimed to predict and prevent the impact of serious diseases from occurring. Together, we are employing and testing not just one approach but a range of innovative initiatives to help improve patient outcomes and address population health.

Alliance for the Million Hearts®

Amgen is part of the CDC Foundation’s Alliance for the Million Hearts campaign, an initiative focused on changing the way people think about and embrace CVD prevention — promoting simple and sustained steps that people can take to help protect their heart health.

Read the Article

AMGA ASCVD Best Practices Learning Collaborative

Amgen has joined Novartis in support of the American Medical Group Association Foundation’s new atherosclerotic cardiovascular disease (ASCVD) Best Practices Learning Collaboration, a 15-month initiative focused on helping medical groups develop strategies to improve the management and treatment of patients with ASCVD.

View Press Release

CardioHealth Alliance

Amgen joined the CardioHealth Alliance to expedite evidence-based solutions for prevention and care of cardiovascular, renal, and cardiometabolic diseases. The CardioHealth Alliance brings together a multidisciplinary group of experts to improve disease care pathways and expedite the implementation of evidence into practice.

View Press Release

Cardiometabolic Center Alliance

Amgen is a supporting sponsor of the Cardiometabolic Center Alliance (CMCA), founded by Saint Luke’s Mid America Heart Institute. The CMCA seeks to establish Cardiometabolic Centers of Excellence nationwide aimed at transforming the treatment and improving the lives of those living with cardiovascular disease and diabetes.

View Press Release

Check. Change. Control. Cholesterol™

Amgen has partnered with American Heart Association on Check. Change. Control. Cholesterol™ program, which aims to reduce the number of Americans who have heart attacks and strokes by improving cholesterol management of high-risk cardiovascular disease patients through a multifaceted approach.

See the Program


Amgen has partnered with American College of Cardiology (ACC) on TRANSFORM: ACS, a program that aims to initiate lipid-lowering treatment closer to hospital discharge for ACS patients.

View Press Release